The Immunologic Treatment Of Cancer

Continuous cultures of fused cells secreting antibody of predefined specificity

1975 • 17,037 citations

Physiological Functions of Glucocorticoids in Stress and Their Relation to Pharmacological Actions*

1984 • 3,073 citations

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin

1987 • 2,006 citations

A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

1986 • 1,787 citations

Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors

2016 • 1,466 citations

Cachectin: More Than a Tumor Necrosis Factor

1987 • 1,457 citations

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1982 • 1,001 citations

Alpha Interferon for Induction of Remission in Hairy-Cell Leukemia

1984 • 833 citations

Expression in Escherichia coli of chemically synthesized genes for human insulin.

1979 • 813 citations

RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION

1985 • 756 citations

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1985 • 737 citations

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1984 • 687 citations

Effect of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor on Myelopoiesis in the Acquired Immunodeficiency Syndrome

1987 • 633 citations

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1985 • 600 citations

Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

1985 • 566 citations

Short-Term Metabolic Effects of Recombinant Human Insulin-like Growth Factor I in Healthy Adults

1987 • 554 citations

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

1981 • 516 citations

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

1980 • 503 citations

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

1987 • 478 citations

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

1986 • 459 citations

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

1988 • 432 citations

Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3.

1986 • 408 citations

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.

1987 • 404 citations

Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer Patients

1982 • 381 citations

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1985 • 376 citations

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1985 • 368 citations

Clinical effects and toxicity of interleukin-2 in patients with cancer

1986 • 359 citations

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.

1983 • 355 citations

Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia

1983 • 337 citations

Renal cell carcinoma: antitumor effects of leukocyte interferon.

1983 • 320 citations

Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes

1986 • 307 citations

Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.

1987 • 292 citations

A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous Melanoma

1982 • 282 citations

Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.

1980 • 270 citations

Preliminary Observations on the Effect of Human Leukocyte Interferon in Non-Hodgkin's Lymphoma

1978 • 267 citations

RESPONSE OF CUTANEOUS T CELL LYMPHOMA TO THERAPY WITH HYBRIDOMA MONOCLONAL ANTIBODY

1981 • 265 citations

In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia

1981 • 260 citations

Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.

1985 • 259 citations

Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells

1981 • 253 citations

Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.

1981 • 250 citations

Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells.

1987 • 248 citations

Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?

1984 • 247 citations

Passive Immunotherapy of Cancer in Animals and Man

1977 • 245 citations

Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome.

1988 • 225 citations

The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.

1980 • 223 citations

Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.

1986 • 220 citations

Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.

1987 • 212 citations

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.

1987 • 211 citations

Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.

1987 • 204 citations

The Preparation and Cytotoxic Properties of Antibody‐Toxin Conjugates

1982 • 199 citations

Tumor Imaging with Radioactive Metal Chelates Conjugated to Monoclonal Antibodies

1982 • 196 citations

Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.

1985 • 185 citations

Adjuvant Immunotherapy with BCG in Treatment of Regional-Lymph-Node Metastases from Malignant Melanoma

1976 • 181 citations

Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues.

1985 • 177 citations

Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.

1984 • 165 citations

Prospectively randomized trial of adjuvant active‐specific immunotherapy for human colorectal cancer

1985 • 164 citations

Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.

1984 • 157 citations

Basic principles and applications of monoclonal antibodies in the management of carcinomas: the Richard and Hinda Rosenthal Foundation award lecture.

1986 • 148 citations

Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo.

1987 • 135 citations

In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.

1987 • 134 citations

Bladder Cancer Immunotherapy

1982 • 133 citations

Monoclonal mouse antibodies raised against human lung carcinoma

1987 • 132 citations

The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.

1987 • 129 citations

Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.

1986 • 126 citations

Biological Response Modifiers

1989 • 125 citations

Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients.

1985 • 114 citations

Pilot trial of murine monoclonal antibodies in patients with advanced melanoma.

1985 • 112 citations

Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.

1985 • 112 citations

Studies of a high molecular weight human melanoma-associated antigen.

1983 • 111 citations

Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide.

1985 • 110 citations

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

1983 • 109 citations

Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

1986 • 109 citations

Radioimmunodetection of Cutaneous T-Cell Lymphoma with¹¹¹In-Labeled T101 Monoclonal Antibody

1986 • 102 citations

Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors

1989 • 101 citations

A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.

1986 • 99 citations

Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.

1987 • 99 citations

Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.

1987 • 97 citations

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

1987 • 91 citations

Intraperitoneal Administration of Interleukin-2 in Patients With Cancer

1986 • 91 citations

Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.

1986 • 88 citations

Neoplastic B Cells as Targets for Antibody‐Ricin A Chain Immunotoxins

1982 • 85 citations

Clinical and Immunologic Effects of Recombinant Leukocyte A Interferon in Eight Patients With Advanced Cancer

1982 • 79 citations

Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients.

1986 • 78 citations

The Progesterone Antagonist RU 486

1987 • 77 citations

Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody.

1986 • 75 citations

Pharmacokinetic study of partially pure gamma-interferon in cancer patients.

1984 • 74 citations

Tumour localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumour growth with adriamycin-antibody conjugates

1982 • 68 citations

Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells.

1985 • 66 citations

Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

1983 • 66 citations

Separation and functional studies of the human lymphokine-activated killer cell.

1987 • 65 citations

Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.

1987 • 61 citations

Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells

1985 • 61 citations

Intralesional Immunotherapy of Melanoma with BCG

1976 • 59 citations

A Fifteen‐month Double‐blind Cross‐over Study of the Efficacy and Antigenicity of Human and Pork Insulins

1984 • 59 citations

Therapeutic options in renal-cell carcinoma.

1985 • 58 citations

Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies

1987 • 58 citations

Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma.

1986 • 56 citations

A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma.

1987 • 52 citations

Melanoma: therapeutic options with recombinant interferons.

1985 • 52 citations

Monoclonal Antibody Imaging of Human Melanoma

1986 • 48 citations

Interferon alfa-2b in the treatment of chronic granulocytic leukemia.

1986 • 48 citations

The immunoaugmenting effects of cancer chemotherapeutic agents.

1986 • 45 citations

Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma.

1985 • 39 citations

Active immunotherapy against cancer: present status.

1986 • 39 citations

Monoclonal antitumor antibodies in the lymphatics.

1984 • 38 citations

Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against thy 1.1 antigen.

1981 • 37 citations

In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody.

1987 • 37 citations

Interferons in the treatment of multiple myeloma

1987 • 36 citations

Immunoregulation with Levamisole

1980 • 35 citations

Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results.

1986 • 34 citations

In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.

1987 • 32 citations

Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.

1982 • 28 citations

Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia.

1986 • 27 citations

Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody.

1986 • 19 citations

Specificity, efficacy, and toxicity of radioimmunotherapy in erythroleukemic mice.

1984 • 19 citations

Current condition and prognosis of tumor immunotherapy: a second opinion.

1984 • 18 citations

Interferons in the treatment of multiple myeloma.

1986 • 15 citations

Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell.

1987 • 15 citations

Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: A possible approach to the immunotherapy of human tumors

1987 • 15 citations

In vivo enhancement of antitumor immunity by interleukin 2-rich lymphokines.

1986 • 14 citations

Interferon in the treatment of malignant lymphoma.

1985 • 12 citations

Interferon--The First Quarter Century

1982 • 11 citations

Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A).

1985 • 9 citations

Therapeutic options in hairy-cell leukemia.

1985 • 9 citations

Phase I study of recombinant beta-interferon given by four-hour infusion.

1987 • 8 citations

In vivo use of cytokines

1984 • 2 citations

Protocol design for lymphokine testing in clinical studies of human cancer.

1986 • 1 citations